Appendix :

Appendix, Table A1: Baseline characteristics of patients lost to follow-up

	Total		Survival		Lost to follow-up		
	Number of patients	%	Number of patients	%	Number of patients	%	p
Sex							
Men	410	40.8	407	40.9	3	33.3	
Women	595	59.2	589	59.1	6	66.7	0.745
Age, mean (standard-deviation)	87.1 (6.6)		87.4 (9.2)		87.1 (6.7)		0.862
Nursing home							
	191	19	191	19.2	0	0	0.221
Smoking							
	154	15.3	153	15.4	1	11.1	
Unknown	810	80.6	803	80.6	7	77.8	0.424
Dyslipidemia							
	169	16.8	168	16.9	1	11.1	1.000
Diabetes							
	271	27	269	27	2	22.2	1.000
Ongoing disease							
	570	56.7	566	56.8	4	44.4	
Unknown	24	2.4	23	2.3	1	11.1	0.218
Cognition							
	260	25.9	255	25.6	5	55.6	0.055
Recent hospitalization							
	249	24.8	247	24.8	2	22.2	1.000
More than 2 hospitalizations in an intensive care unit							
	4	0.4	4	0.4	0	0	1.000
Frailty							
	464	46.2	459	46.1	5	55.6	
Unknown	275	27.4	272	27.3	3	33.3	0.690

p, p-value exact Fischer test

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Support Palliat Care

Appendix, Table A2: Bivariate analysis of predictive risk factors of short-term mortality

	Beta coefficient	OR	OR 95% CI	p
Male	0.7187	2.05	1.12-3.77	0.020
Age	0.0489	1.05	1.00-1.10	0.056
Nursing home residency	0.8453	2.33	1.04-5.23	0.040
Weight loss	1.0134	2.75	1.49-5.11	0.001
Self-reported exhaustion	1.0712	2.92	1.41-6.04	0.004

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Support Palliat Care

Appendix, Table A3: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 95% confidence intervals at different risk score cut-off points.

Risk score cut point	Sensitivity	Specificity	Positive predictive value	Negative predictive value	False positive rate
≥ 0	1	0	-	-	1
≥ 3	0.98	0.06	0.12	0.96	0.94
≥ 4	0.98	0.14	0.12	0.98	0.86
≥ 5	0.98	0.14	0.13	0.98	0.86
≥ 6	0.96	0.25	0.14	0.98	0.75
≥ 7	0.92	0.35	0.16	0.97	0.65
≥ 8	0.92	0.36	0.16	0.97	0.64
≥ 9	0.88	0.43	0.17	0.96	0.57
≥ 10	0.81	0.51	0.18	0.95	0.49
≥ 11	0.73	0.58	0.19	0.94	0.42
≥ 12	0.58	0.74	0.23	0.93	0.26
≥ 13	0.58	0.75	0.24	0.93	0.25
≥ 14	0.54	0.78	0.24	0.93	0.22
≥ 15	0.46	0.83	0.26	0.92	0.17
≥ 16	0.31	0.93	0.37	0.91	0.07
≥ 17	0.21	0.97	0.48	0.90	0.03
≥ 18	0.19	0.97	0.45	0.90	0.03
≥ 19	0.10	0.98	0.39	0.89	0.02
≥ 20	0.10	0.99	0.50	0.89	0.01
≥ 23	0.02	0.99	0.33	0.89	0.01
≥ 25	0	0.99	0.00	0.88	0.01
> 25	0	1	-	-	0

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Support Palliat Care

Appendix, Figure A1: Proportions of observed and predicted deaths (Derivation cohort)

Appendix, Figure A2. Prediction of short-term mortality with WHALES Score

Appendix, Figure A3. Receiver operating characteristic curve for the performance of short-term mortality risk score


Figure A4. Proportion of observed and predicted deaths according to the mortality risk score (Validated cohort)